Bipolar depression: A new role for atypical antipsychotics?

Bipolar Disorders, Supplement

Volumn 7, Issue 4, 2005, Pages 34-40

  Keck Jr , Paul E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Atypical antipsychotics; Bipolar depression; Bipolar disorder; Olanzapine; Quetiapine

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; FLUOXETINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; ZIPRASIDONE;

AKATHISIA; APPETITE DISORDER; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BODY WEIGHT DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; CONSCIOUSNESS DISORDER; CONSTIPATION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EMOTIONAL DISORDER; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOMANIA; HYPOTHYROIDISM; INFECTION; MANIA; MIXED MANIA AND DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MORBIDITY; MORTALITY; NAUSEA; NERVOUSNESS; POLYURIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SLEEP; SLEEP DISORDER; SOMNOLENCE; SUICIDE; SYMPTOMATOLOGY; TREMOR; WEIGHT GAIN; XEROSTOMIA;

EID: 23044490143     PISSN: 13992406     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2005.00213.x     Document Type: Review

References (32)

1. Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60: 261-269.
2. Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-537.
3. Post RM, Denicoff KD, Leverich GS et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003; 64: 680-690.
4. Dilsaver SC, Chen Y-W, Swann AC, Shoaib AM, Tsai-Dilsaver Y, Krajewski KJ. Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and pure-mania. Psychiatry Res 1997; 73: 47-56.
5. Jamison KR. Suicide and bipolar disorder. J Clin Psychiatry 2000; 61 (Suppl. 9): 47-51.
6. Keller MB, Lavori PW, Coryell W et al. Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness. JAMA 1986; 255: 3138-3142.
7. Nemeroff CB. Safety of available agents used to treat bipolar disorder: focus on weight gain. J Clin Psychiatry 2003; 64: 532-539.
8. Mitchell PB, Wilhelm K, Parker G, Austin MP, Rutgers P, Malhi GS. The clinical features of bipolar depression: a comparison with matched major depressive disorder patients. J Clin Psychiatry 2001; 62: 212-216.
9. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001; 3: 22-27.
10. Soares JC. Recent advances in the treatment of bipolar mania, depression, mixed states, and rapid cycling. Int Clin Psychopharmacol 2000; 15: 183-196.
11. Zornberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993; 13: 397-408.
12. Nemeroff CB. An ever-increasing pharmacopoeia for the management of patients with bipolar disorder. J Clin Psychiatry 2000; 61 (Suppl. 13): 19-25.
13. Calabrese JR, Woyshville MJ. Lithium therapy: limitations and alternatives in the treatment of bipolar disorders. Ann Clin Psychiatry 1995; 7: 103-112.
14. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J Clin Psychiatry 1999; 60 (Suppl. 2): 77-84.
15. Kasper S, Stamenkovic M, Letmaier M, Schreinzer D. Atypical antipsychotics in mood disorders. Int Clin Psychopharmacol 2002; 17 (Suppl. 3): S1-S10.
16. Calabrese JR, Bowden CL, Sachs GS et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79-88.
17. Bowden CL, Asnis GM, Ginsberg LD, Bentley B, Leadbetter R, White R. Safety and tolerability of lamotrigine for bipolar disorder. Drug Saf 2004; 27: 173-184.
18. Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995; 152: 1130-1138.
19. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164: 549-550.
20. Vieta E, Goikolea JM, Corbella B et al. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study. J Clin Psychiatry 2001; 62: 818-825.
21. Keck PE Jr, Wilson DR, Strakowski SM et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 1995; 56: 466-470.
22. Vieta E, Reinares M, Corbella B et al. Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharmacol 2001; 21: 469-473.
23. Ghaemi SN, Cherry EL, Katzow JA, Goodwin FK. Does olanzapine have antidepressant properties? A retrospective preliminary study. Bipolar Disord 2000; 2: 196-199.
24. Post RM, Leverich GS, Altshuler LL et al. An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). Bipolar Disord 2003; 5: 310-319.
25. Mullen J, Jibson MD, Sweitzer D, the QUEST Study Group, A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the Quetiapine Experience with Safety and Tolerability (QUEST) study. Clin Ther 2001; 23: 1839-1854.
26. Jones M, Huizar K. Quetiapine monotherapy for mania associated with bipolar disorder. Poster presented at the 5th Annual International Conference on Bipolar Disorder, Pittsburgh, PA, USA, 12-14 June, 2003.
27. Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079-1088.
28. Macfadden W, Calabrese JR, McCoy R, Minkwitz M, Wilson E, Mullen J. Antianxiety effects analysis of quetiapine in bipolar depression. Poster presented at the 157th Annual Meeting of the American Psychiatric Association, New York, NY, USA, May 1-6, 2004.
29. Calabrese JR, Keck PE Jr, Macfadden W et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2004; in press.
30. Calabrese J, Macfadden W, McCoy R, Minkwitz M, Wilson E, Mullen J. Double-blind, placebo-controlled study of quetiapine in bipolar depression. Poster presented at the 157th Annual Meeting of the American Psychiatric Association, New York, NY, USA, May 1-6, 2004.
31. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193-213.
32. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29: 321-326.